Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AERI Aerie Pharmaceuticals	$15.25	$15.23	$4.81 ▼ $15.37	$753.61M	-0.06	974,748 shs	600 shs
ALVO Alvotech	$10.28 +3.4%	$9.29	$7.35 ▼ $14.65	$3.10B	-0.02	136,782 shs	268,212 shs
IBRX ImmunityBio	$2.53 -5.6%	$2.63	$1.83 ▼ $7.63	$2.23B	0.33	5.57 million shs	6.25 million shs
SRRK Scholar Rock	$30.00 -1.5%	$30.85	$6.76 ▼ $46.98	$2.85B	0.37	1.27 million shs	825,200 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AERI Aerie Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ALVO Alvotech	-2.17%	-4.97%	+18.90%	-19.06%	-29.00%
IBRX ImmunityBio	+1.13%	+0.37%	-0.37%	-21.64%	-61.38%
SRRK Scholar Rock	-0.85%	-1.20%	-3.73%	-19.20%	+160.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AERI Aerie Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	1.7771 of 5 stars	3.5	2.0	0.0	0.0	2.6	0.0	0.6
IBRX ImmunityBio	1.8288 of 5 stars	3.6	1.0	0.0	0.0	1.9	1.7	0.6
SRRK Scholar Rock	3.9792 of 5 stars	3.5	0.0	0.0	4.4	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AERI Aerie Pharmaceuticals	0.00	N/A	N/A	N/A
ALVO Alvotech	3.00	Buy	$18.00	75.10% Upside
IBRX ImmunityBio	3.20	Buy	$12.25	384.19% Upside
SRRK Scholar Rock	3.00	Buy	$42.67	42.22% Upside

Current Analyst Ratings Breakdown

Latest AERI, ALVO, SRRK, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/14/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
5/12/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/12/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/5/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/28/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/23/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/16/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/9/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/31/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AERI Aerie Pharmaceuticals	$194.13M	3.88	N/A	N/A	($3.32) per share	-4.59
ALVO Alvotech	$585.60M	5.29	N/A	N/A	N/A	∞
IBRX ImmunityBio	$31.22M	71.52	N/A	N/A	($0.88) per share	-2.88
SRRK Scholar Rock	$33.19M	85.82	N/A	N/A	$3.12 per share	9.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AERI Aerie Pharmaceuticals	-$74.81M	-$0.77	N/A	N/A	N/A	-17.09%	N/A	-2.00%	N/A
ALVO Alvotech	-$551.73M	$0.37	N/A	51.40	N/A	-123.47%	N/A	-35.87%	N/A
IBRX ImmunityBio	-$583.20M	-$0.58	N/A	N/A	N/A	-8,016.83%	N/A	-110.02%	8/11/2025 (Estimated)
SRRK Scholar Rock	-$165.79M	-$2.53	N/A	N/A	N/A	N/A	-145.60%	-91.83%	N/A

Latest AERI, ALVO, SRRK, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A
3/26/2025	Q4 2024	ALVO Alvotech	-$0.74	-$0.24	+$0.50	-$0.24	$97.99 million	$153.34 million
3/3/2025	Q4 2024	IBRX ImmunityBio	-$0.26	-$0.15	+$0.11	-$0.09	$8.74 million	$7.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AERI Aerie Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AERI Aerie Pharmaceuticals	N/A	2.27	1.92
ALVO Alvotech	N/A	2.69	1.92
IBRX ImmunityBio	N/A	2.68	2.64
SRRK Scholar Rock	0.63	3.88	3.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AERI Aerie Pharmaceuticals	95.94%
ALVO Alvotech	N/A
IBRX ImmunityBio	8.58%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
AERI Aerie Pharmaceuticals	4.44%
ALVO Alvotech	0.46%
IBRX ImmunityBio	76.79%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AERI Aerie Pharmaceuticals	376	49.42 million	47.22 million	Optionable
ALVO Alvotech	4	301.48 million	N/A	Not Optionable
IBRX ImmunityBio	590	882.62 million	115.67 million	Optionable
SRRK Scholar Rock	140	94.95 million	75.64 million	Optionable

AERI, ALVO, SRRK, and IBRX Headlines

Recent News About These Companies

BNP Paribas Financial Markets Sells 13,394 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 23 at 3:17 AM | marketbeat.com

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 22 at 7:39 AM | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Bought by Woodline Partners LP

May 22 at 6:18 AM | marketbeat.com

Soleus Capital Management L.P. Invests $7.24 Million in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 21 at 8:08 AM | marketbeat.com

Rafferty Asset Management LLC Sells 37,595 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

May 21 at 5:41 AM | marketbeat.com

Polar Asset Management Partners Inc. Trims Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 20 at 5:29 AM | marketbeat.com

Dimensional Fund Advisors LP Lowers Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 20 at 3:14 AM | marketbeat.com

HC Wainwright Boosts Earnings Estimates for Scholar Rock

May 20 at 1:31 AM | marketbeat.com

Wedbush Forecasts Scholar Rock's Q2 Earnings (NASDAQ:SRRK)

May 20 at 1:18 AM | americanbankingnews.com

What is Wedbush's Estimate for Scholar Rock Q2 Earnings?

May 20 at 1:16 AM | marketbeat.com

Deutsche Bank AG Has $8 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 19, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Stock Holdings Lessened by Sphera Funds Management LTD.

May 18, 2025 | marketbeat.com

What is Wedbush's Forecast for Scholar Rock FY2029 Earnings?

May 18, 2025 | americanbankingnews.com

Polar Capital Holdings Plc Reduces Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 17, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by Janus Henderson Group PLC

May 17, 2025 | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025 | businesswire.com

MPM Bioimpact LLC Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 16, 2025 | marketbeat.com

400,000 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Acquired by Paradigm Biocapital Advisors LP

May 16, 2025 | marketbeat.com

Patient Square Capital LP Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 16, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Ensign Peak Advisors Inc

May 16, 2025 | marketbeat.com

Baird Financial Group Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

May 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AERI, ALVO, SRRK, and IBRX Company Descriptions

Aerie Pharmaceuticals NASDAQ:AERI

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Alvotech NASDAQ:ALVO

$10.28 +0.34 (+3.42%)

Closing price 04:00 PM Eastern

Extended Trading

$10.30 +0.02 (+0.15%)

As of 04:04 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

ImmunityBio NASDAQ:IBRX

$2.53 -0.15 (-5.60%)

Closing price 04:00 PM Eastern

Extended Trading

$2.54 +0.01 (+0.40%)

As of 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Scholar Rock NASDAQ:SRRK

$30.00 -0.46 (-1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$29.68 -0.32 (-1.05%)

As of 05:19 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time